Isaac Brigth

San Carlos, California, United States
Dr. Bright is an entrepreneurial physician with a robust track-record building shareholder value for more than a decade. Following completion of his MD at Stanford, Isaac served as Financial Analyst at CIBC in 2004. Dr. Bright was an esteemed Howard E. Mitchell Fellow, earning his MBA at The Wharton School between 2004-2006. Isaac joined the Medtronic Corporate Development team in 2006, and was promoted to Director of BD for Medtronic Neuromodulation in 2008. Dr. Bright joined the leadership team of QuantaLife, Inc. in 2009 and drove the Company’s financing and strategic transaction initiatives through the successful trade-sale to Bio-Rad Laboratories in 2011. Dr. Bright spent more than 4 years serving as the only American Partner for Merieux Developement, with €220M under management. Isaac served briefly as VP, Corp. Dev. for Synthetic Biologics before joining HealthTell as CBO in 2017. Isaac led the Company's successful capitalization, launch, and growth since inception.
Speaking In
10:30 AM - 10:45 AM
Tuesday, October 22
Founded in 2017, RubrYc Therapeutics, Inc. integrates massively parallel in silico simulation and…